Waters Corp (WAT) FinancialsWATWaters Corp

Waters Corp (WAT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Chemistry Consumables, accounting for 42.9% of total sales, equivalent to $543.00M. Other significant revenue streams include Waters Instrument Systems and TA Instrument Systems. Understanding this composition is critical for investors evaluating how WAT navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Waters Corp maintains a gross margin of 29.79%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.61%, while the net margin is -8.27%. These profitability ratios, combined with a Return on Equity (ROE) of 1.91%, provide a clear picture of how effectively WAT converts its operational activities into shareholder value.

In the context of the broader market, WAT competes directly with industry leaders such as A and IDXX. With a market capitalization of $40.74B, it holds a significant position in the sector. When comparing efficiency, WAT's gross margin of 29.79% stands against A's 55.48% and IDXX's 64.04%. Such benchmarking helps identify whether Waters Corp is trading at a premium or discount relative to its financial performance.

Waters Corp has shown strong revenue growth, with Q2 2026 revenue at $1.645 billion and a gross margin of 29.79% in Q2 2026, down from previous quarters, indicating a need for attention on profitability.